ANXA1 and type 2 diabetes mellitus: Thus, we propose that elevated levels of ANXA1 may represent a novel biomarker for the development of hepatosteatosis and that hrANXA1 or its peptide mimetics may be useful in the treatment of T2D and/or its complications.